Review: Glycoprotein IIb/IIIa inhibitors reduced death or MI in acute coronary syndromes not routinely scheduled for revascularization

Bates, Eric R.
July 2002
ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p2
Academic Journal
Presents information on a study that examined the efficacy and safety of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes not routinely scheduled for early coronary revascularization. Data sources; Study selection; Data extraction; Main results; Conclusion.


Related Articles

  • Should patients with unstable coronary syndromes routinely undergo cardiac catheterization and appropriate revascularization? Gazewood, John // Journal of Family Practice;Sep2001, Vol. 50 Issue 9, p739 

    The article discusses research being done on comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. It references a study by C. P. Cannon et al published in the 2001 issue of the "New...

  • Revascularization for Stable Coronary Artery Disease. Abrams, Jonathan // Internal Medicine Alert;11/29/2007, Vol. 29 Issue 22, p171 

    Exceptional attention has been paid to the recent publication of the COURAGE Trial (April 2007) regarding the efficacy of percutaneous coronary intervention (PCI) in stable coronary disease patients. Whereas in acute coronary syndromes, including STEMI and unstable angina, there is reasonable...

  • COURAGE and Management of Stable CAD. Karpman, Harold L. // Internal Medicine Alert;9/29/2008, Vol. 30 Issue 18, p141 

    The article presents an abstract and a commentary on the article "COURAGE and Management of Stable CAD," by Harold L. Karpman.

  • Sequential left internal mammary artery usage for complex left anterior descending coronary artery revascularization. Aydin, Ufuk; Ata, Yusuf // International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 4, p1188 

    A letter to the editor is presented on the article "Alternative Option in Patients With Multisegmental Left Anterior Descending Coronary Artery Disease for Providing Complete Myocardial Revascularization," by A. Gucu and colleagues, in a previous issue.

  • PTCR Glycoprotein Receptor Antagonists Unproved. Kirchner, Jeffrey T. // American Family Physician;11/15/2000, Vol. 62 Issue 10, p2328 

    Presents information on a study by W.W. O'Neill and others that evaluated whether oral xemilofiban, a glycoprotein IIb/IIIa receptor antagonist, would provide sustained protection from the need for revascularization, myocardial infarction or death following percutaneous transluminal coronary...

  • Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. Dyke, Cornelius M.; Jennings, Lisa K.; Maier, George; Andreou, Costa; Daly, Robert; Tamberella III, Michael R. // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2007, Vol. 12 Issue 1, p54 

    The article investigates on the use of glycoprotein IIb-IIIa inhibitor eptifibatide in patients with acute coronary syndromes who are undergoing coronary artery bypass grafting. It also discusses the impact of platelet inhibition on patients with acute coronary syndromes. It states that platelet...

  • Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization. Topol, Eric J.; Moliterno, David J.; Herrmann, Howard C.; Powers, Eric R.; Grines, Cindy L.; Cohen, David J.; Cohen, Eric A.; Bertrand, Michel; Neumann, Franz-Josef; Stone, Gregg W.; DiBattiste, Peter M.; Yakubov, Steven J.; DeLucca, Paul T.; Demopoulos, Laura // New England Journal of Medicine;06/21/2001, Vol. 344 Issue 25, p1888 

    Background: In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal myocardial infarction at 30 days. We assessed whether there are differences in safety or...

  • Future Trials of Antiplatelet Agents in Cardiac Ischemia. Throckmorton, Douglas C. // New England Journal of Medicine;06/21/2001, Vol. 344 Issue 25, p1937 

    Editorial. Discusses trials reported in the June 21, 2001 issue of 'The New England Journal of Medicine,' on aspects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary revascularization. Uncertainty about value of treatment with inhibitors because of inconsistent...

  • Glycoprotein IIb/IIIa Receptor Antagonists: A Comparative Review of Their Use in Percutaneous Coronary Intervention. Can M. Nguyen; Robert A. Harrington // American Journal of Cardiovascular Drugs;2003, Vol. 3 Issue 6, p423 

    Antiplatelet therapy is critical during percutaneous coronary intervention (PCI) as it reduces the incidence of abrupt closure and distal thrombi embolization, which are significant acute peri-procedural complications likely responsible for the clinical adverse outcomes with PCI, namely death,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics